Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCT-200
- Development stage
- Preclinical
- Lead developer
- Bio-Cancer Treatment International
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Administration
- Intravenous
01
Overview
BCT-200 is a pegylated recombinant human arginase 1 (pegArg1) developed as an arginine-depleting agent for the treatment of cancers and autoimmune disorders. It is a modified version of BCT-100, designed to maximize drug stability and safety. The mechanism involves enzymatic depletion of extracellular arginine, which targets tumors and immune cells that are auxotrophic for arginine, thereby inhibiting their growth or function. The drug is being developed primarily by Bio-Cancer Treatment International Limited for use in neoplasms (including solid tumors), immune system diseases, and skin/musculoskeletal diseases[1][3][8].
02
Targets
ARG1 (Arginase 1)
Beyond the preview
Go deeper on BCT-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCT-200.